Union Health Ministry Makes Cough Syrup Sales Strictly Prescription Only

The Union Health Ministry has officially made the sale of cough syrups strictly prescription-only across the country, aiming to curb substance abuse and address critical safety concerns. On Tuesday, June 16, 2026, the ministry issued a notification amending the Drugs Rules, 1945, to remove cough syrups from Schedule K, meaning they can no longer be purchased over the counter in Hyderabad and other parts of India.

Previously, cough syrups were grouped under Schedule K alongside common over-the-counter medicines such as paracetamol, aspirin, pain balms, gels, and lozenges. This classification allowed general stores and medical shops to sell them without requiring a doctor's prescription. With the new amendment, cough syrups have been separated from this category, making a formal medical prescription mandatory for procurement.

The federal decision comes in the wake of severe safety incidents, including a tragedy in Madhya Pradesh last August and September, where more than 20 children died after allegedly consuming contaminated cough syrup. Additionally, several deaths among children have been reported in other countries where syrups manufactured in India have been exported.

Beyond safety concerns regarding contamination, the amendment aims to address widespread substance abuse. In Hyderabad and various other urban and rural areas, authorities have noted a significant population of individuals with substance use disorders who are dependent on cough syrups.

Most cough syrups available in the market are codeine-based formulations, which are opioid derivatives. When consumed in quantities that exceed recommended medical dosages, these syrups can lead to severe physical and psychological dependence. Due to their easy accessibility without a prescription, they have frequently been used for recreational abuse to induce sedative or euphoric effects, acting as gateway drugs for youth.

By removing cough syrups from Schedule K, the government hopes to regulate access and enable better monitoring of these habit-forming drugs at the retail level, curbing a public health issue that was previously difficult to control.